Besnier's prurigo
Methodology & AI Transparency ⓘ
Besnier's prurigo Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Besnier's prurigo (L20.0) in Skin & Dermatology relies on clinical dermatologic lesion in Besnier's prurigo (L20.0: morphology exam), guiding step-wise therapeutic adjustments toward Fasting Lipids & in Besnier's prurigo (L20.0: ALT (if systemic) (Within baseline reference limits (L20.0)).
- 2 Real-world patient consensus: Clinical coding for Besnier's prurigo uses ICD-10 L20.0 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Clinicians assessing Besnier's prurigo focus on cutaneous immune skewing in Besnier's prurigo (L20.0: (Th2/IL-4/IL-13 in atopic) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Besnier's prurigo: maintaining Affected Body Surface in Besnier's prurigo (L20.0: Area (BSA /) within Clear or Almost Clear (IGA 0–1) (L20.0).
Ask our AI Specialists anything about Besnier's prurigo
What Is Besnier's prurigo?
Clinical triage of Besnier's prurigo (L20.0) in Skin & Dermatology relies on clinical dermatologic lesion in Besnier's prurigo (L20.0: morphology exam), guiding step-wise therapeutic adjustments toward Fasting Lipids & in Besnier's prurigo (L20.0: ALT (if systemic) (Within baseline reference limits (L20.0)).
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Besnier's prurigo (L20.0) features cutaneous immune skewing in Besnier's prurigo (L20.0: (Th2/IL-4/IL-13 in atopic). therapeutic stabilization in skin & dermatology is verified against Fasting Lipids & in Besnier's prurigo (L20.0: ALT (if systemic).
Common Symptoms & Clinical Signs
- • Presentation of Besnier's prurigo (L20.0): recurrent flares triggered in Besnier's prurigo (L20.0: by UV exposure,)
- • Secondary Besnier's prurigo clinical sign: persistent erythematous plaques, in Besnier's prurigo (L20.0: scaly patches, pruritic)
- • Symptom flares in Besnier's prurigo correlating with Affected Body Surface in Besnier's prurigo (L20.0: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L20.0)
- • Functional skin & dermatology impact requiring clinical dermatologic lesion in Besnier's prurigo (L20.0: morphology exam) evaluation (L20.0)
Besnier's prurigo Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L20.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Besnier's prurigo (L20.0: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L20.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Besnier's prurigo (L20.0: ALT (if systemic) | Within baseline reference limits (L20.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Besnier's prurigo (L20.0: & hs-CRP) | 25(OH)D 40–65 ng/mL (L20.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Besnier's prurigo
Treatment selection for Besnier's prurigo depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Besnier's prurigo)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of a New Botulinum Toxin (HU-014) Versus Existing: What a 267-Participant Study Found HU-014 was noninferior to existing onabotulinumtoxin A in the treatment of glabellar lines at a 1:1 dose ratio, and both products were well tolerated. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] • 2021-03-01 • Phase III Randomized Trial | N = 267 | 93/100 | PMID 33481449 ↗ |
| What the Latest Evidence Really Says About Placebo effects on From searches in four databases, 34 articles were included in the quantitative analyses. The Journal of investigative dermatology • 2015-05-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 25609025 ↗ |
| Can This Approach Help? Inside the Latest Research on Aesthetic Improvements Over Time: Long-Term Efficacy and Additional Outcomes of Additional endpoints, including pGAIS, iGAIS, and MAS scores, corroborate prior ULTRAI/II findings and demonstrate the efficacy of incobotulinumtoxinA for simultaneous treatment of UFLs. Journal of cosmetic dermatology • 2025-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40968493 ↗ |
| Managing Eczema: Can Berdazimer gel for molluscum contagiosum Make a Real Difference? (What a 209-Person Study Found) Berdazimer gel showed favorable efficacy regardless of AD status. Pediatric dermatology • 2024-01-15 • Phase III Randomized Trial | N = 209 | 88/100 | PMID 38413239 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of Significant improvements in PROs were demonstrated with both abrocitinib doses vs. Journal of the European Academy of Dermatology and Venereology : JEADV • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34779063 ↗ |
Besnier's prurigo Patient Community & “People Like Me” Threads
Filter Besnier's prurigo community threads and patient logs by age, biological sex, dosage, and treatment duration.